By Evans Matthews
For many men, skin conditions like acne and rosacea are assumed to be relics of adolescence or cosmetic inconveniences. Yet across the globe, adult males are increasingly seeking medical care for these chronic inflammatory disorders, which often persist well into middle age. The challenge for clinicians is not just acute management, but optimizing long-term pharmacotherapy in a way that balances efficacy, safety, and adherence.
Adult male acne differs subtly from its adolescent counterpart. Hormonal influences, occupational exposures, and lifestyle factors such as shaving practices and stress, can all exacerbate the condition. Persistent truncal acne and deep nodulocystic lesions are not uncommon. Meanwhile, rosacea, often underdiagnosed in men, tends to present later but more severely, sometimes progressing to phymatous changes if left untreated.
“Men frequently delay seeking treatment until symptoms are advanced,” notes Dr. Ibrahim Al-Khatib, a consultant dermatologist based in Dubai. “By then, we’re dealing with not just inflammation, but scarring and significant psychosocial impact.”
Pharmacotherapy remains the cornerstone of management, but long-term strategies require nuance. For acne, topical retinoids continue to anchor therapy due to their comedolytic and anti-inflammatory properties. When combined with benzoyl peroxide or topical antibiotics, they can reduce bacterial resistance while maintaining control. However, adherence remains a major barrier, particularly among men who may prefer simpler regimens.
Systemic therapies are often necessary for moderate to severe cases. Oral antibiotics, such as doxycycline, are widely used, but their prolonged use raises concerns about antimicrobial resistance. As a result, dermatology guidelines increasingly emphasize limiting antibiotic duration and transitioning to maintenance therapies.
Isotretinoin, though highly effective, requires careful monitoring due to its side effect profile. “In adult men, isotretinoin can be transformative,” says Dr. Laura Mendes, a clinical researcher in São Paulo. “But long-term remission depends on appropriate dosing and follow-up, not just the initial course.”
Rosacea management presents a different therapeutic landscape. Topical agents like metronidazole, azelaic acid, and ivermectin are first-line treatments for mild to moderate disease. For more persistent inflammation, oral tetracyclines at sub-antimicrobial doses offer anti-inflammatory benefits without contributing significantly to resistance.
Emerging therapies are also reshaping the field. Brimonidine and oxymetazoline creams, for instance, target persistent facial erythema by vasoconstriction, offering symptomatic relief that was previously difficult to achieve pharmacologically. Meanwhile, research into the skin microbiome and immune modulation is opening new avenues for targeted treatments.
A key consideration in long-term care is the overlap between acne and rosacea, which can complicate diagnosis and treatment. Misclassification may lead to suboptimal outcomes, particularly when therapies for one condition exacerbate the other. Clinicians are increasingly adopting individualized treatment plans that consider skin type, comorbidities, and patient preferences.
Adherence remains the linchpin of success. “You can prescribe the most advanced therapy, but if the patient doesn’t use it consistently, outcomes will suffer,” emphasizes Dr. Al-Khatib. Simplified regimens, patient education, and realistic expectations are critical components of care.
Globally, access to dermatologic care and medications varies widely, influencing treatment choices. In low-resource settings, cost-effective and accessible therapies must be prioritized, often requiring creative adaptation of international guidelines.
Ultimately, managing acne and rosacea in adult men is less about quick fixes and more about sustained control. With evolving pharmacologic options and a growing emphasis on personalized care, the outlook is improving, but only if long-term strategies are thoughtfully applied.
English